Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$88.21M

FY 2025 · Annual

Investing Cash Flow

-$96.75M

FY 2025 · Annual

Financing Cash Flow

$170.31M

FY 2025 · Annual

-62.1% YoY

Cash Flow Statement

USD
Metric
FY2020
Dec 2020
FY2021
Dec 2021
FY2022
Dec 2022
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.74M)(19.32M)(9.93M)(83.72M)(105.43M)
Depreciation & Amortization93K91K114K27K83K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.88M(28K)(1.66M)11.59M(2.56M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.1M(411K)(783K)3.46M693K
Other Working Capital776K383K(878K)8.13M(3.25M)
Other Non-Cash Items43K497K561K14.27M19.7M
Operating Cash Flow(7.73M)(18.76M)(10.91M)(57.84M)(88.21M)
Capital Expenditures(19K)(43K)(2K)(189K)(209K)
Acquisitions (Net)00000
Purchases of Investments000(329.94M)(520.96M)
Sales of Investments0000424.42M
Other Investing Activities00000
Investing Cash Flow(19K)(43K)(2K)(330.13M)(96.75M)
Debt Repayment(408K)0000
Common Stock Issued48.86M23.09M0449.54M170.32M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow48.45M23.09M0449.54M170.32M
Effect of Forex Changes000(37.43M)0
Net Change in Cash40.71M4.29M(10.91M)24.14M(14.64M)
Free Cash Flow(7.74M)(18.81M)(10.91M)(58.03M)(88.42M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$105.4M
+ D&A$83.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$2.6M
+ Other Non-Cash$19.7M
= Operating Cash Flow-$88.2M
- Capex-$209.0K
= Free Cash Flow-$88.4M

Analysis

FY2025 free cash flow is -$88.4M. FCF conversion is 83.9% of net income. Operating cash flow was -$88.2M, with capex of -$209.0K. The largest bridge item is Other Non-Cash at $19.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 2, 2026
8-KCurrent reportOct 26, 2026

Does ORKA generate free cash flow?

Oruka Therapeutics, Inc. (ORKA) generated -$88.42M of free cash flow in fiscal 2025.

How much operating cash flow does ORKA produce?

Operating cash flow was -$88.21M, before capital expenditures of $209,000.00.